Evaluating the Openness of COVID-19-Related Randomized Controlled Trials

The openness of COVID-19-related randomized controlled trials (RCTs) has yet to be comprehensively assessed. Demonstrating the importance of ensuring their results are rigorous and transparent, RCTs are frequently referred to as the “gold standard” of evidence.

We are examining the openness of COVID-19 trials along several dimensions, including open access to publications, data sharing, preregistration, and the availability of other research materials (e.g. protocols).

This presentation describes some of our methods and describes where the project is heading next.